| 2023-11-15 |
详情>>
股本变动：
变动后总股本404.89万股
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-69.57美元,归母净利润-2.76亿美元,同比去年增长-324.06%
|
| 2023-10-27 |
股东大会：
将于2023-11-21召开股东大会
会议内容 ▼▲
- 1.To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.0001 per share (“Series A Preferred Stock”) (the “Conversion Proposal” or “Proposal No. 1”);
2.To approve an amendment and restatement of the Aeglea BioTherapeutics, Inc. 2016 Equity Incentive Plan (the “Equity Compensation Plan Proposal” or “Proposal No. 2”);
3.To approve an amendment to our Certificate of Incorporation, as amended and restated (“Certificate of Incorporation”), to increase the number of authorized shares of the Common Stock from 20,000,000 to 400,000,000 (the “Authorized Shares Proposal” or “Proposal No. 3”);
4.To approve the adjournment or postponement of the Special Meeting, if necessary, to continue to solicit votes for Proposals Nos. 1, 2, and/or 3 (the “Adjournment Proposal” or “Proposal No. 4”).
|
| 2023-09-08 |
复牌提示：
2023-09-08 09:36:32 停牌，复牌日期 2023-09-08 09:41:32
|
| 2023-09-08 |
详情>>
拆分方案：
每25.0000合并分成1.0000股
|
| 2023-08-11 |
详情>>
业绩披露：
2023年中报每股收益-2.48美元,归母净利润-2.36亿美元,同比去年增长-403.65%
|
| 2023-05-11 |
详情>>
业绩披露：
2023年一季报每股收益-0.2美元,归母净利润-1842.2万美元,同比去年增长24.61%
|
| 2023-04-17 |
股东大会：
将于2023-06-06召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors of Aeglea, each to serve until the 2026 annual meeting of stockholders.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve, on a non-binding advisory basis, the compensation of Aeglea’s named executive officers as disclosed in the proxy statement for the 2023 Annual Meeting.
4.To approve an amendment to Aeglea’s restated certificate of incorporation (the “Restated Certificate of Incorporation”) to effect a reverse stock split of Aeglea’s common stock at a ratio ranging from 1-for-10 shares up to a ratio of 1-for-25 shares, which ratio will be selected by Aeglea’s board of directors (the “Reverse Stock Split”).
5.To approve an amendment and restatement of our 2016 Equity Incentive Plan.
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2023-03-02 |
详情>>
业绩披露：
2020年年报每股收益-1.52美元,归母净利润-8089.3万美元,同比去年增长-3.37%
|
| 2023-03-02 |
详情>>
业绩披露：
2022年年报每股收益-0.99美元,归母净利润-8381.5万美元,同比去年增长-27.38%
|
| 2022-11-03 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-0.81美元,归母净利润-6499.3万美元,同比去年增长-43.3%
|
| 2022-08-04 |
详情>>
业绩披露：
2022年中报每股收益-0.63美元,归母净利润-4675.9万美元,同比去年增长-86.68%
|
| 2022-05-05 |
详情>>
业绩披露：
2022年一季报每股收益-0.37美元,归母净利润-2443.6万美元,同比去年增长-34.13%
|
| 2022-04-21 |
股东大会：
将于2022-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors of Aeglea BioTherapeutics, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To approve, on a non-binding advisory basis, the compensation of the company’s named executive officers as disclosed in the proxy statement for the 2022 Annual Meeting.
4.To approve, on a non-binding advisory basis, the frequency of future votes on the compensation of the company’s named executive officers.
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-03-08 |
详情>>
业绩披露：
2021年年报每股收益-1美元,归母净利润-6580.1万美元,同比去年增长18.66%
|
| 2021-11-04 |
详情>>
业绩披露：
2021年三季报(累计)每股收益-0.69美元,归母净利润-4535.5万美元,同比去年增长22.04%
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-22 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors of Aeglea BioTherapeutics, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021.
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-05-28 |
股东大会：
将于2020-06-08召开股东大会
会议内容 ▼▲
- 1.To elect two Class I directors of Aeglea BioTherapeutics, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020.
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-04-22 |
股东大会：
将于2019-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors of Aeglea BioTherapeutics, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019.
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-03-07 |
财报披露：
美东时间 2019-03-07 盘后发布财报
|
| 2018-09-06 |
股东大会：
将于2018-10-08召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our 2016 Equity Incentive Plan.
2.To transact such other business as may properly come before the Special Meeting or any adjournment or postponement thereof.
|
| 2018-07-11 |
详情>>
内部人交易：
Quinn Anthony G.股份增加3307.00股
|
| 2018-04-16 |
股东大会：
将于2018-06-07召开股东大会
会议内容 ▼▲
- 1.To elect two Class II directors of Aeglea BioTherapeutics, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.
3.To approve an amendment to the 2016 Employee Stock Purchase Plan to provide for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year for the remaining term of the plan equal to (a) 1.0% of the number of issued and outstanding shares of common stock on December 31 of the immediately preceding year, or (2) a lesser amount as approved by the Board.
|
| 2017-04-21 |
股东大会：
将于2017-06-07召开股东大会
会议内容 ▼▲
- 1.To elect three Class I directors of Aeglea BioTherapeutics, Inc. each to serve until the third annual meeting of stockholders following this meeting and until his or her successor has been elected and qualified or until his or her earlier resignation or removal.
2.To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017.
3.To re-approve the Internal Revenue Code Section 162(m) limits of our 2016 Equity Incentive Plan to preserve our ability to receive corporate income tax deductions that may become available pursuant to Section 162(m).
|